Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1247579
1. Grasemann C, Herrmann R, Starschinova J, Gertsen M, Palmert MR, Grasemann H: Effects of fetal exposure to high-fat diet or maternal hyperglycemia on L-arginine and nitric oxide metabolism in lung. Nutr Diabetes; 2017 Feb 20;7(2):e244

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of fetal exposure to high-fat diet or maternal hyperglycemia on L-arginine and nitric oxide metabolism in lung.
  • BACKGROUND/OBJECTIVES: Alterations in the L-arginine/nitric oxide (NO) metabolism contribute to diseases such as obesity, metabolic syndrome and airway dysfunction.
  • The objective of this work was to study the effects of intrauterine exposures to maternal hyperglycemia and high-fat diet (HFD) on pulmonary L-arginine/NO metabolism in mice.
  • CONCLUSIONS: These data suggest that maternal hyperglycemia and HFD can cause alterations in the pulmonary L-arginine/NO metabolism in offspring.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2004 Jul 15;170(2):148-53 [15070820.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Oct 29;239(3):875-7 [9367862.001]
  • [Cites] Am J Respir Crit Care Med. 2011 Oct 1;184(7):779-85 [21719758.001]
  • [Cites] Pediatr Res. 2016 Feb;79(2):278-86 [26539661.001]
  • [Cites] Am J Respir Crit Care Med. 2013 Jan 15;187(2):153-9 [23204252.001]
  • [Cites] PLoS One. 2015 Jun 22;10(6):e0129850 [26098111.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2015 Aug 15;309(4):L360-8 [26092997.001]
  • [Cites] PLoS One. 2012;7(11):e50210 [23209676.001]
  • [Cites] Chest. 2013 Aug;144(2):405-10 [23412513.001]
  • [Cites] Am J Cardiol. 2001 Nov 15;88(10 ):1201-3 [11703973.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Oct 1;176(7):650-8 [17641156.001]
  • [Cites] J Appl Physiol (1985). 2008 Jun;104(6):1727-35 [18323466.001]
  • [Cites] J Clin Invest. 1998 May 15;101(10):2112-8 [9593767.001]
  • [Cites] Mediators Inflamm. 2014;2014:323526 [25177109.001]
  • [Cites] Eur Respir J. 2014 Feb;43(2):647-8 [24488993.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1896-900 [16507636.001]
  • [Cites] Clin Sci (Lond). 1998 Aug;95(2):115-28 [9680492.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2008 Mar;294(3):L498-504 [18192591.001]
  • [Cites] Curr Vasc Pharmacol. 2016;14 (3):237-59 [26899560.001]
  • [Cites] J Endocrinol. 2013 Mar 15;217(1):69-81 [23503967.001]
  • [Cites] Am J Respir Crit Care Med. 2011 Feb 15;183(4):441-8 [20851922.001]
  • [Cites] Diab Vasc Dis Res. 2013 Sep;10 (5):436-41 [23766377.001]
  • (PMID = 28218737.001).
  • [ISSN] 2044-4052
  • [Journal-full-title] Nutrition & diabetes
  • [ISO-abbreviation] Nutr Diabetes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Zhang AY, Ji XW, Zhang AJ, Guan LX, Huang J, Wang JX: Role of Genetic Polymorphism of Angiotensin-Converting Enzyme, Plasminogen Activator Inhibitor-1 and Endothelial Nitric Oxide Synthase in the Prognosis of Coronary Artery Disease. Cardiol Res; 2010 Dec;1(1):8-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Genetic Polymorphism of Angiotensin-Converting Enzyme, Plasminogen Activator Inhibitor-1 and Endothelial Nitric Oxide Synthase in the Prognosis of Coronary Artery Disease.
  • All patients were detected I/D polymorphism of angiotensin-converting enzyme (ACE) gene, 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene, and G894→T mutation of endothelial nitric oxide synthase (eNOS) gene.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Atherosclerosis. 2007 Nov;195(1):172-80 [17118372.001]
  • [Cites] Circulation. 1997 May 20;95(10):2358-67 [9170397.001]
  • [Cites] Eur Heart J. 2002 Dec;23(24):1955-62 [12473258.001]
  • [Cites] J Mol Cell Cardiol. 2005 Oct;39(4):667-79 [16087188.001]
  • [Cites] IUBMB Life. 1999 Aug;48(2):205-7 [10794598.001]
  • [Cites] Circulation. 1996 May 1;93(9):1630-3 [8653866.001]
  • [Cites] Diabetes. 2006 Jul;55(7):2140-7 [16804086.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):33-7 [9012634.001]
  • [Cites] Scand J Clin Lab Invest. 1998 Oct;58(6):491-5 [9832341.001]
  • [Cites] Heart. 2002 Jun;87(6):525-8 [12010932.001]
  • [Cites] Biochemistry. 1989 Jun 27;28(13):5311-8 [2476171.001]
  • [Cites] J Am Coll Cardiol. 1996 Jul;28(1):162-7 [8752809.001]
  • [Cites] J Biol Chem. 1993 May 25;268(15):10739-45 [8388372.001]
  • [Cites] Thromb Haemost. 2000 Jul;84(1):78-82 [10928474.001]
  • [Cites] Circulation. 1999 Oct 5;100(14):1515-20 [10510054.001]
  • [Cites] Coron Artery Dis. 2006 Feb;17(1):35-9 [16374139.001]
  • [Cites] Thromb Haemost. 1997 Mar;77(3):605-6 [9066021.001]
  • [Cites] Int J Cardiol. 2002 Nov;86(1):71-6 [12243851.001]
  • [Cites] Atherosclerosis. 1998 Jul;139(1):153-9 [9699903.001]
  • [Cites] Circulation. 1997 Jan 7;95(1):59-62 [8994417.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):152-6 [9484978.001]
  • [Cites] Thromb Res. 2001 Jul 15;103(2):103-7 [11457467.001]
  • [Cites] Hypertension. 1998 Sep;32(3):521-6 [9740620.001]
  • [Cites] Br J Haematol. 2000 Jul;110(1):135-8 [10930990.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2082-7 [9351375.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):531-4 [10747309.001]
  • [Cites] Rev Cardiovasc Med. 2004;5 Suppl 3:S14-21 [15303081.001]
  • [Cites] Metabolism. 1998 Oct;47(10):1258-62 [9781631.001]
  • (PMID = 28352370.001).
  • [ISSN] 1923-2829
  • [Journal-full-title] Cardiology research
  • [ISO-abbreviation] Cardiol Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Angiotensin-converting enzyme / Coronary artery disease / Endothelial nitric oxide synthase / Gene polymorphism / Major adverse cardiovascular event / Plasminogen activator inhibitor-1 / Prognosis
  •  go-up   go-down


3. Mishra S, Mishra BB: Study of Lipid Peroxidation, Nitric Oxide End Product, and Trace Element Status in Type 2 Diabetes Mellitus with and without Complications. Int J Appl Basic Med Res; 2017 Apr-Jun;7(2):88-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of Lipid Peroxidation, Nitric Oxide End Product, and Trace Element Status in Type 2 Diabetes Mellitus with and without Complications.
  • Malondialdehyde (MDA) is a stable end product of lipid peroxidation.
  • Accumulative evidences suggest that hyperglycemia in Type 2 DM can produce major changes in nitric oxide (NO) production as well as in its action.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabet Med. 2000 Mar;17(3):171-80 [10784220.001]
  • [Cites] World Health Organ Tech Rep Ser. 1985;727:1-113 [3934850.001]
  • [Cites] Clin Biochem. 2001 Feb;34(1):65-70 [11239518.001]
  • [Cites] Clin Chim Acta. 2004 Aug 16;346(2):161-70 [15256317.001]
  • [Cites] Clin Chem. 1997 Jul;43(7):1209-14 [9216458.001]
  • [Cites] J Immunol. 1988 Oct 1;141(7):2407-12 [3139757.001]
  • [Cites] Diabetes Res Clin Pract. 2001 Oct;54(1):33-9 [11532328.001]
  • [Cites] Mol Aspects Med. 2003 Feb-Jun;24(1-3):39-52 [12537988.001]
  • [Cites] J Cardiovasc Nurs. 2003 Jan-Mar;18(1):62-8 [12537092.001]
  • [Cites] Ophthalmologica. 2003 Sep-Oct;217(5):342-6 [12913324.001]
  • [Cites] Diabetes. 1978 Feb;27(2):102-7 [624438.001]
  • [Cites] Diabetes. 2010 Sep;59(9):2152-9 [20484137.001]
  • [Cites] Diabetes Care. 1991 Nov;14(11):1050-6 [1797486.001]
  • [Cites] J Am Coll Nutr. 1998 Apr;17(2):109-15 [9550453.001]
  • [Cites] Int J Appl Basic Med Res. 2011 Jan;1(1):31-5 [23776769.001]
  • [Cites] Clin Chim Acta. 1978 Nov 15;90(1):37-43 [719890.001]
  • [Cites] Saudi Med J. 2006 Mar;27(3):344-50 [16532095.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):2002-12 [7504210.001]
  • [Cites] J Clin Invest. 1991 Feb;87(2):432-8 [1991829.001]
  • [Cites] Diabetologia. 1992 Aug;35(8):771-6 [1511805.001]
  • [Cites] Free Radic Biol Med. 1991;10(5):339-52 [1855674.001]
  • [Cites] Hormones (Athens). 2009 Oct-Dec;8(4):279-85 [20045801.001]
  • [Cites] Br Med Bull. 1993 Jul;49(3):481-93 [8221017.001]
  • [Cites] Metabolism. 2009 Oct;58(10):1477-82 [19592053.001]
  • [Cites] J Am Coll Nutr. 2001 Jun;20(3):212-8 [11444416.001]
  • [Cites] Diabetes Care. 2004 Jul;27(7):1761-73 [15220264.001]
  • [Cites] Swiss Med Wkly. 2003 May 17;133(19-20):289-92 [12844272.001]
  • [Cites] Clin Chem Lab Med. 2001 Feb;39(2):109-15 [11341743.001]
  • [Cites] N Am J Med Sci. 2013 Mar;5(3):213-9 [23626958.001]
  • (PMID = 28584737.001).
  • [ISSN] 2229-516X
  • [Journal-full-title] International journal of applied & basic medical research
  • [ISO-abbreviation] Int J Appl Basic Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Lipid peroxidation / malondialdehyde / nitric oxide / oxidative stress / trace element
  •  go-up   go-down


Advertisement
4. Maccallini C, Amoroso R: Targeting neuronal nitric oxide synthase as a valuable strategy for the therapy of neurological disorders. Neural Regen Res; 2016 Nov;11(11):1731-1734

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting neuronal nitric oxide synthase as a valuable strategy for the therapy of neurological disorders.
  • In this short review we analyze some promising advancements in the search of new bioactive molecules targeting neuronal nitric oxide synthase (nNOS), an enzyme deputed to the biosynthesis of nitric oxide (NO).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Pharmacol. 2013 Aug;169(7):1417-29 [23617570.001]
  • [Cites] Nat Med. 2010 Dec;16(12 ):1439-43 [21102461.001]
  • [Cites] ChemMedChem. 2016 Aug 19;11(16):1695-9 [27377568.001]
  • [Cites] J Med Chem. 2012 Jan 26;55(2):943-55 [22175766.001]
  • [Cites] Clin Ther. 2010 Jan;32(1):146-60 [20171420.001]
  • [Cites] J Neurosci. 1999 Dec 1;19(23):10250-61 [10575022.001]
  • [Cites] Science. 2002 Oct 25;298(5594):846-50 [12399596.001]
  • [Cites] Springerplus. 2016 May 17;5:637 [27330903.001]
  • [Cites] Mini Rev Med Chem. 2013 Jul;13(9):1305-10 [23621655.001]
  • [Cites] Bioorg Med Chem Lett. 2012 Mar 1;22(5):1980-4 [22318159.001]
  • [Cites] Front Cell Neurosci. 2015 Aug 17;9:322 [26347610.001]
  • [Cites] Brain Res Bull. 2016 Jul;125:99-105 [27237129.001]
  • [Cites] J Cell Biol. 2005 Jan 3;168(1):117-26 [15631993.001]
  • [Cites] Br J Pharmacol. 2013 Mar;168(5):1255-65 [23072468.001]
  • [Cites] J Med Chem. 2015 Feb 12;58(3):1064-6 [25602734.001]
  • (PMID = 28123402.001).
  • [ISSN] 1673-5374
  • [Journal-full-title] Neural regeneration research
  • [ISO-abbreviation] Neural Regen Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Keywords] NOTNLM ; NMDAR / PSD95 / amidines / carbonic anhydrase / inhibitors / neurological diseases / neuronal nitric oxide synthase
  •  go-up   go-down


5. Al-Ali MK, Howarth PH: Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia. Saudi Med J; 2001 Mar;22(3):249-53
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia.
  • OBJECTIVE: Nitric oxide is known to be present in the exhaled air of normal subjects and at higher concentrations in asthmatics.
  • The aim of this study was to measure exhaled nitric oxide levels in patients admitted to hospital with acute exacerbations of asthma, or chronic obstructive pulmonary disease, or with pneumonia.
  • METHODS: Within 24 hours of admission exhaled nitric oxide levels were measured by a chemiluminescent analyzer in 11 patients with acute sever asthma, 19 patients with acute exacerbation of chronic obstructive pulmonary disease, and in 12 patients with pneumonia.
  • RESULTS: On admission median exhaled nitric oxide levels (range) were significantly higher in asthmatics 22 (9.3-74) parts per billion in comparison to patients with chronic obstructive pulmonary disease 10.3 (2.7-34) parts per billion; p < 0.01, pneumonia 7 (4-17) parts per billion; p<0.001, and normal subjects 8.7 (5-13.3) parts per billion; p < 0.001.
  • Following treatment the asthmatics had a significant reduction in their exhaled nitric oxide levels from 22 (9.3-74) parts per billion on day 1 to 9.7 (5.7-18.3) parts per billion on day 28; p = 0.005.
  • A strong negative correlation existed between peak expiratory flow rate measurements and exhaled nitric oxide levels in asthmatics on day 28 (r = -0.70; p = 0.017).
  • CONCLUSION: Acute exacerbations of asthma are associated with increased levels of exhaled nitric oxide in contrast to exacerbations of chronic obstructive pulmonary disease and acute pneumonia.
  • Exhaled nitric oxide may be a useful indirect marker of asthmatic airway inflammation.
  • The differing time course of response of nitric oxide to peak flow measures suggests that these two measures are reflecting differing airway events.
  • [MeSH-major] Asthma / metabolism. Breath Tests. Lung Diseases, Obstructive / metabolism. Nitric Oxide / analysis. Pneumonia / metabolism


6. Shan J, Ni Y, Dong W, Xu JH, Pan L, Li HY, Yang X, Wu SW, Chen YH, Deng FR, Guo XB: [The effect of short-term exposure to ambient NO(2) on lung function and fractional exhaled nitric oxide in 33 chronic obstructive pulmonary disease patients]. Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jun 06;51(6):527-532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The effect of short-term exposure to ambient NO(2) on lung function and fractional exhaled nitric oxide in 33 chronic obstructive pulmonary disease patients].
  • <b>Objectives:</b> To investigate the effect of short-term exposure to ambient NO(2) has influence on lung function and fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) patients.
  • We excluded patients with asthma, bronchial tensor, lung cancer and other respiratory disorders other than chronic obstructive pulmonary disease and occupational exposure and chest trauma surgery patients.
  • At the same time, the atmospheric NO(2) data of Beijing environmental monitoring station near the residence of each patient during the study period were collected from 1 day to 7 days lag before the measurement.
  • <b>Conclusions:</b> Short term exposure to ambient NO(2) may bring down pulmonary function in COPD patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28592098.001).
  • [ISSN] 0253-9624
  • [Journal-full-title] Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
  • [ISO-abbreviation] Zhonghua Yu Fang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Keywords] NOTNLM ; Fractional exhaled nitric oxide / Lung function / Nitrogen dioxide / Pulmonary disease, chronic obstructive
  •  go-up   go-down


7. Huang Z, Fu J, Zhang Y: Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. J Med Chem; 2017 May 23;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.
  • The increasing understanding of the role of nitric oxide (NO) in cancer biology has generated significant progress in the use of NO donor-based therapy to fight cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28505442.001).
  • [ISSN] 1520-4804
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Ko SY, Chang YS, Park WS: Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn. J Korean Med Sci; 1998 Oct;13(5):500-6
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn.
  • We observed clinical response to inhaled nitric oxide (iNO) in 12 neonates with persistent pulmonary hypertension of the newborn (PPHN).
  • Two infants showed no response to iNO (one diaphragmatic hernia and one suspected pulmonary hypoplasia).
  • We conclude that iNO therapy could improve oxygenation in high percentage of newborn infants with severe PPHN of various underlying conditions except pulmonary hypoplasia.
  • [MeSH-major] Nitric Oxide / therapeutic use. Persistent Fetal Circulation Syndrome / therapy. Vasodilator Agents / therapeutic use

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 9811179.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Vasodilator Agents; 31C4KY9ESH / Nitric Oxide
  • [Other-IDs] NLM/ PMC3054528
  •  go-up   go-down


9. Deerojanawong J, Leartphichalak P, Chanakul A, Sritippayawan S, Samransamruajkit R: Exhaled nitric oxide, pulmonary function, and disease activity in children with systemic lupus erythematosus. Pediatr Pulmonol; 2017 May 22;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exhaled nitric oxide, pulmonary function, and disease activity in children with systemic lupus erythematosus.
  • AIM: To determine the association among fractional exhaled nitric oxide (FENO), pulmonary function, and disease activity in children with systemic lupus erythematosus (SLE).
  • All eligible participants had disease activity, FENO, and pulmonary function evaluated and re-evaluated at 6-month follow-up.
  • At baseline, 20.8% had abnormal pulmonary functions (all restrictive defects) and increased to 29.2% at follow-up (isolated restrictive defect 25% and restrictive with diffusion defect 4.2%).
  • Most of their disease activities at baseline and second assessment were non-active (58.3%, 70.8%) or mild disease activities (20.8% both).
  • FENO should be considered as an additional pulmonary function to evaluate disease activity in children with SLE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28544706.001).
  • [ISSN] 1099-0496
  • [Journal-full-title] Pediatric pulmonology
  • [ISO-abbreviation] Pediatr. Pulmonol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; children / disease activity / fractional exhaled nitric oxide / pulmonary function / systemic lupus erythematosus
  •  go-up   go-down


10. Hrstka SC, Li X, Nelson TJ, Wanek Program Genetics Pipeline Group: NOTCH1-Dependent Nitric Oxide Signaling Deficiency in Hypoplastic Left Heart Syndrome Revealed Through Patient-Specific Phenotypes Detected in Bioengineered Cardiogenesis. Stem Cells; 2017 Apr;35(4):1106-1119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1-Dependent Nitric Oxide Signaling Deficiency in Hypoplastic Left Heart Syndrome Revealed Through Patient-Specific Phenotypes Detected in Bioengineered Cardiogenesis.
  • To better understand a mechanistic basis through which NOTCH1 contributes to heart development, human induced pluripotent stem cells (hiPSCs) were created from the HLHS-affected parent-proband triad and differentiated into cardiovascular cell lineages for molecular characterization.
  • Optimization of conditions to procure HLHS-hiPSC-cardiomyocytes led to an approach that compensated for dysregulated nitric oxide (NO)-dependent Notch signaling in the earliest specification stages.
  • No discernable differences in calcium dynamics were observed between the bioengineered cardiomyocytes derived from the proband and the parents.
  • We conclude that in vitro modeling with HLHS-hiPSCs bearing NOTCH1 mutations facilitated the discovery of a NO-dependent signaling component essential for cardiovascular cell lineage specification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
  • (PMID = 28142228.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cardiac / Developmental biology / Differentiation / Drug target / Hypoplastic left heart syndrome / NOTCH1 / Pluripotent stem cells
  •  go-up   go-down






Advertisement